This research protocol examines the combined use of Retatrutide, Tirzepatide, and 5-Amino-1MQ in the context of metabolic regulation, energy balance, and adipose tissue signaling. Retatrutide and Tirzepatide are multi-receptor agonists studied for their activity on incretin pathways, including GLP-1 and GIP (with Retatrutide also engaging glucagon receptors), which are associated in research with appetite modulation, glucose metabolism, and energy expenditure. 5-Amino-1MQ is investigated for its role as an NNMT (nicotinamide N-methyltransferase) inhibitor, with research exploring its potential effects on cellular energy utilization and fat storage mechanisms. These compounds remain investigational and are intended strictly for research use in controlled settings, not for clinical or therapeutic application.